Company overview

Kestra Medical Technologies supplies patients at elevated risk of sudden cardiac arrest with ASSURE, a wearable device that continuously monitors heart rhythms and automatically delivers an electric shock when it detects life-threatening ventricular arrhythmias. Its FDA-approved use is for adults who are not candidates for, or refuse, an implantable defibrillator. ASSURE anchors the company’s Cardiac Recovery System, which also provides a patient app, remote monitoring through Kestra CareStation, and alert and emergency-response services.

Nearly all revenue comes from monthly ASSURE leases. Kestra bills Medicare, Medicaid, private insurers and other healthcare organizations directly, while patients pay deductibles, coinsurance and other uncovered costs. Revenue depends on providers prescribing ASSURE, patients wearing it, and insurers covering and paying for its use. The duration of patient use also affects billing; Medicare reimbursement requires medical necessity and compliance with applicable local coverage rules.

Patients return the equipment when their prescriptions end. A third-party partner tests and reconditions reusable components for the next patient, so keeping devices available depends on returns and refurbishment as well as manufacturing. Kestra outsources manufacturing and relies on single or limited suppliers for some components. It has no regulatory approval to commercialize its products outside the United States.